Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss ...

Nevro (NVRO) could be a solid choice for investors ... the stock -- for the current and following years is tracked by the system. The power of a changing earnings picture in determining near ...

Analysts at StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO – Get Free Report) in a research note issued on ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year ...

In addition to the U.S. market release, Nevro introduced the HFX iQ SCS system in select European countries in January 2025 following the receipt of CE Mark Certification in November 2024.

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the ...

Nevro Corp. engages in the development of medical ... It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of ...

Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period ...

MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.